Adrenocortical carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Key molecular events that contribute to formation of adrenocortical cancer are IGF2 overexpression, TP53-inactivating mutations, and constitutive activation of the Wnt/b-catenin signalling pathway via activating mutations of the b-catenin gene.
|
27387247 |
2016 |
Adrenocortical carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Abnormal methylation at the IGF2/H19 locus is common in adrenocortical carcinomas.
|
23093492 |
2013 |
Adrenocortical carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Because the overexpression of the IGF-II gene is a frequent feature of adrenal carcinoma, we searched for the presence of GHRH-R SVs in these tumours.
|
15853821 |
2005 |
Adrenocortical carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The genetic predisposition to adrenocortical cancer in children has been well established in the Li-Fraumeni and Beckewith-Wiedeman syndromes due to germline p53 mutation located at 17p13 and dysregulation of the imprinted IGF-2 locus at 11p15, respectively.
|
16001332 |
2005 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
IGF-II mRNA levels were more than 10-fold higher in hormonally active adrenocortical carcinomas than in normal adult adrenals, and increased IGF-II-like immunoreactivity was detectable in these carcinomas.
|
8370710 |
1993 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
Everolimus therapy for progressive adrenocortical cancer.
|
23417626 |
2013 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma.
|
25089899 |
2014 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.
|
27535174 |
2016 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
Clinicopathological features, biochemical and molecular markers in 5 patients with adrenocortical carcinoma.
|
21521927 |
2011 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
p53 Stabilization induces cell growth inhibition and affects IGF2 pathway in response to radiotherapy in adrenocortical cancer cells.
|
23028800 |
2012 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated that estrogen receptor (ER) alpha (ESR1) increases proliferation of adrenocortical carcinoma (ACC) through both an estrogen-dependent and -independent (induced by IGF-II/IGF1R pathways) manner.
|
26131713 |
2015 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
IGF2 role in adrenocortical carcinoma biology.
|
31378849 |
2019 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overexpression of insulin growth factor 2 (IGF2) is a hallmark of adrenocortical carcinomas and pheochromocytomas.
|
26400872 |
2015 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line.
|
10425444 |
1999 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The xenografts precisely reproduced the dysregulation of the insulin-like growth factor (IGF) system [overexpression of the IGF-II and IGF-binding protein-2 (IGFBP-2) genes] typical of adrenocortical carcinoma.
|
10965887 |
2000 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We previously demonstrated that, in adrenocortical carcinoma (ACC), ERα is upregulated and that estradiol activates the IGF-II/IGF1R signaling pathways defining the role of this functional cross-talk in H295R ACC cell proliferation.
|
29112114 |
2017 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In four hormonally active adrenocortical carcinomas, very low levels of H19 ribonucleic acid (RNA) were detected, whereas IGF-II was highly expressed.
|
7531713 |
1995 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Hormonally active adrenocortical carcinomas and virilizing adenomas express insulin-like growth factor II gene abundantly.
|
9694575 |
1998 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have identified overexpression of insulin-like growth factor 2 (IGF-2) and constitutive activation of β-catenin as key factors involved in the development of adrenocortical carcinoma.
|
21386792 |
2011 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
It is evident, therefore, that high levels of IGF-II in combination with overexpression of the IGF-I-receptor can provide a significant growth advantage for adrenocortical carcinoma cells and thus contribute to the highly malignant phenotype of this rare type of cancer.
|
15241731 |
2004 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
RNA analysis indicated that the adrenocortical carcinomas expressed less H19 but more IGF-II RNAs than normal adrenal tissues did.
|
11889182 |
2002 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
Otherwise, IGF-II was mainly overexpressed in adult adrenocortical carcinomas (270.5 +/- 130.2 vs. 16.1 +/- 13.3; P = 0.0001).
|
18611974 |
2008 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
IGF2 is often overexpressed in many tumours including adrenal carcinomas.
|
9367863 |
1997 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
IGF-II overexpression has been consistently demonstrated in adult adrenocortical carcinomas.
|
18611974 |
2008 |